Skip to content

COVID-19: A Scope Research on Epidemiology and Clinical Course

COVID-19: A Scope Research on Epidemiology and Clinical Course

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05046769
Acronym
COVID-Scope
Enrollment
5000
Registered
2021-09-16
Start date
2020-04-28
Completion date
2025-12-31
Last updated
2021-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19, SARS CoV 2 Infection, Sequelae of; Infection

Keywords

Covid19, Cohort Studies, Long COVID, Secondary Attack Rate, Serology, Epidemiology

Brief summary

Severe Acute Respiratory Syndrome (SARS) Coronavirus (CoV) 2 infection and the associated coronavirus disease 2019 (COVID-19) are the most recent international health threat challenging our ability to protect populations, to avoid severe outcomes and to understand both the population dynamics of this new condition and the breath of individual responses. Gathering information on the clinical course of the disease and the risk of transmission is essential to design effective therapeutic solutions and preventive measures. The aim of the study proposed, to be carried out at University Hospital Center of São João (CHUSJ), is to recruit and follow-up a cohort of patients diagnosed with SARS-CoV-2 infection, to evaluate the clinical course of SARS-CoV-2 infection and COVID-19 cases, to identify prognostic factors and to measure the risk of reinfection. Additionally, researchers intend to characterize the patients and household contacts to describe the dynamics of infection, to calculate household infection attack rate, and to perform the genetic sequencing of SARS-CoV-2 to understand determinants of disease course (namely long-term effects) and risk of household transmission. A sample of participants, identified during the process of evaluation of symptomatic individuals, at the same institution, and negative for SARS-CoV-2 will be selected as negative controls. Participants will be consecutively recruited and the study is expected to enroll patients as long as the pandemic remains. Information will be gathered based on clinical individual charts, hospital data-bases (example: for administrative data) and individual computer assisted interviews to be performed at pre-defined intervals (3, 12 and 24 months) or according to clinical needs. The project was approved by the local Ethical Committee and the Data Protection relevant authorities.

Interventions

None listed

Sponsors

Centro Hospitalar De São João, E.P.E.
CollaboratorOTHER
IPATIMUP - Instituto De Patologia E Imunologia Molecular Da Universidade Do Porto
CollaboratorOTHER
Instituto de Saude Publica da Universidade do Porto
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Individuals diagnosed with SARS-2-CoV-2 infection treated at CHUSJ and cohabitants able to give informed consent; * individuals who underwent the test for diagnosis of infection by SARS-CoV-2 at CHUSJ with negative result able to give informed consent.

Exclusion criteria

* Inability to obtain informed consent;

Design outcomes

Primary

MeasureTime frameDescription
Clinical, biological, psychosocial characteristics24 monthsDescribe the clinical, biological and psychosocial characteristics SARS-CoV-2 infected inpatients or outpatients identified in our hospital center

Secondary

MeasureTime frameDescription
Household contacts infection attack rate3 monthsCharacterize the dynamics of infection
Genome sequence of SARS-CoV-224 monthsIdentify variants of SARS-CoV-2
Reinfection rate24 monthsNumber and characteristics of reinfections
Prognostic factors of course of disease24 monthsIdentify clinical, biological and social associated with course of disease

Countries

Portugal

Contacts

Primary ContactMargarida Tavares, MD, MPH
mftavares@ispup.up.pt+351222061820

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026